Genetic analysis of SARS-CoV-2 reveals one vaccine could combat all infections
A genetic analysis of SARS-CoV-2 sequences reveal the virus has mutated minimally since December 2019, suggesting only one vaccine is needed to combat COVID-19.
List view / Grid view
A genetic analysis of SARS-CoV-2 sequences reveal the virus has mutated minimally since December 2019, suggesting only one vaccine is needed to combat COVID-19.
The UK government will invest £8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.
Researchers have shown that factoring in valency to vaccine design can improve the number of antibody binding sites on an antigen.
The novel vaccine 4X-SA-GP harnesses the anti-fungal immune response to provide immunity against Staphylococcus aureus (S. aureus) infection.
A potential COVID-19 vaccine, made from a modified vesicular stomatitis virus with the SARS-CoV-2 Spike protein, was shown to protect mice against the virus.
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
A study in older mice with type 2 diabetes revealed a tuberculosis vaccine elicited a strong immune response, making it a promising candidate for the condition.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
Researchers have sequenced SARS-CoV-2, revealing at least six strains with little variability, useful information for vaccine developers.
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
This article outlines the ideal scientific research that should be conducted to design a prophylactic to combat COVID-19.